Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin

Viruses

Volumn 4, Issue 8, 2012, Pages 1264-1278

  Miyamura, Tatsuo ^a   Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Wu, Shuang ^a   Jiang, Xia ^a   Arai, Makoto ^a   Fujiwara, Keiichi ^a   Imazeki, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Anemia; HCV; IL28B; ITPA; SNP; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INOSINE TRIPHOSPHATE; INTERLEUKIN 28B; PEGINTERFERON PLUS RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IL28B GENE; ITPA GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANEMIA; HCV; IL28B; ITPA; SNP; SUSTAINED VIROLOGICAL RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84868607491     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4081264     Document Type: Article

References (52)

1. Di Bisceglie, A.M. Hepatitis C and hepatocellular carcinoma. Hepatology 1997, 26, 34S-38S.
2. Kanda, T., Imazeki, F., Yokosuka, O. New antiviral therapies for chronic hepatitis C. Hepatol. Int. 2010, 4, 548-561.
3. Jensen, D. A new era of hepatitis C therapy begins. N. Engl. J. Med. 2011, 364, 1272-1274.
4. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M.L., Bassendine, M., Spengler, U., Dore, G.J., Powell, E., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41, 1100-1104.
5. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41, 1105-1109.
6. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., Heinzen, E.L., Qiu, P., Bertelsen, A.H., Muir, A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
7. Nakamoto, S., Kanda, T., Imazeki, F., Wu, S., Arai, M., Fujiwara, K., Yokosuka, O. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand. J. Gastroenterol. 2011, 46, 955-961.
8. Miyamura, T., Kanda, T., Nakamoto, S., Wu, S., Fujiwara, K., Imazeki, F., Yokosuka, O. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011, 6, e28617.
9. Lagging, M., Askarieh, G., Negro, F., Bibert, S., Soderholm, J., Westin, J., Lindh, M., Romero, A., Missale, G., Ferrari, C., et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011, 6, e17232.
10. Honda, M., Sakai, A., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shirasaki, T., Horimoto, K., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139, 499-509.
11. Fellay, J., Thompson, A.J., Ge, D., Gumbs, C.E., Urban, T.J., Shianna, K.V., Little, L.D., Qui, P., Bertelsen, A.H., Watson, M., et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010, 464, 40540-40548.
12. Magg, D., Castro, C., Hong, Z., Cameron, C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001, 276, 46094-46098.
13. Contreras, A.M., Hiasa, Y., He, W., Terella, A., Schmidt, E.V., Chung, R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replicon system. J. Virol. 2002, 76, 8505-8517.
14. Kanda, T., Yokosuka, O., Imazeki, F., Tanaka, M., Shino, Y., Shimada, H., Tomonaga, T., Nomura, F., Nagao, K., Ochiai, T., Saisho, H. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: Ribavirin induces mutagenesis in HCV RNA. J. Viral Hepat. 2004, 11, 479-487.
15. Zhou, S., Liu, R., Baroudy, B.M., Malcolm, B.A., Reyes, G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003, 310, 333-342.
16. Tam, R.C., Pai, B., Bard, J., Lim, C., Averett, D.R., Phan, U.T., Milovanovic, T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 1999, 30, 376-382.
17. Thomas, E., Feld, J.J., Li, Q., Hu, Z., Fried, M.W., Liang, T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53, 32-41.
18. Clark, V., Nelson, D.R. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int. 2012, 32, 103-107.
19. Kanda, T., Imazeki, F., Yonemitsu, Y., Mikami, S., Takada, N., Nishino, T., Takashi, M., Tsubota, A., Kato, K., Sugiura, N., et al. Quantification of hepatitis C virus in patients treated with peginterfron-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J. Viral Hepat. 2011, 18, e292-e297.
20. Kanda, T., Imazeki, F., Azemoto, R., Yonemitsu, Y., Mikami, S., Kita, K., Takashi, M., Sunaga, M., Wu, S., Nakamoto, S., et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig. Dis. Sci. 2011, 56, 3335-3342.
21. Miyauchi, T., Kanda, T., Imazeki, F., Mikata, R., Tawada, A., Arai, M., Fujiwara, K., Nakamoto, S., Wu, S., Tanaka, T., et al. Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. Hepatology Int. 2012, in press
22. Tsukiyama-Kohara, K., Yamaguchi, K., Maki, N., Ohta, Y., Miki, K., Mizokami, M., Ohba, K., Tanaka, S., Hattori, N., Nomoto, A., Kohara, M. Antigenicities of group I and II hepatitis C virus polypeptides-Molecular basis of diagnosis. Virology 1993, 192, 430-437.
23. Simmonds, P., Holmes, E.C., Cha, T.A., Chan, S.W., McOmish, F., Irvine, B., Beall, E., Yap, P.L., Kolberg, J., Urdea, M.S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 1993, 74, 2391-2399.
24. McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag, J., Lee, W.M., Mak, C., Garaud, J.J., Albrecht, J.K. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123, 1061-1069.
25. Lo Re, V., 3rd., Teal, V., Localio, A.R., Amorosa, V.K., Kaplan, D.E., Gross, R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: A cohort study. Ann. Intern. Med. 2011, 156, 353-360.
26. Reau, N., Hadziyannis, S.J., Messinger, D., Fried, M.W., Jensen, D.M. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am. J. Gastroenterol. 2008, 103, 1981-1988.
27. Sulkowski, M.S. Anemia in the treatment of hepatitis C virus infection. Clin. Infect. Dis. 2003, 37, S315-S322.
28. Ochi, H., Maekawa, T., Abe, H., Hayashida, Y., Nakano, R., Kubo, M., Tsunoda, T., Hayes, C.N., Kumada, H., Nakamura, Y., Chayama, K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-A genome-wide study of Japanese HCV virus patients. Gastroenterology 2010, 139, 1190-1197.
29. Sakamoto, N., Tanaka, Y., Nakagawa, M., Yatsuhashi, H., Nishiguchi, S., Enomoto, N., Azuma, S., Nishimura-Sakurai, Y., Kakinuma, S., Nishida, N., et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol. Res. 2010, 40, 1063-1071.
30. Hitomi, Y., Cirulli, E.T., Fellay, J., McHutchison, J.G., Thompson, A.J., Gumbs, C.E., Shianna, K.V., Urban, T.J., Goldstein, D.B. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011, 140, 1314-1321.
31. Thompson, A.J., Clark, P.J., Singh, A., Ge, D., Fellay, J., Zhu, M., Zhu, Q., Urban, T.J., Patel, K., Tillmann, H.L., et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J. Hepatol. 2012, 56, 313-319.
32. Tanaka, Y., Kurosaki, M., Nishida, N., Sugiyama, M., Matsuura, K., Sakamoto, N., Enomoto, N., Yatsuhashi, H., Nishiguchi, S., Hino, K., et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum. Mol. Genet. 2011, 20, 3507-3516.
33. Kurosaki, M., Tanaka, Y., Tanaka, K., Suzuki, Y., Hoshioka, Y., Tamaki, N., Kato, T., Yasui, Y., Hosokawa, T., Ueda, K., et al. Relationship between polymorphisms of the inosine triphosphatase gene and anemia or outcome after treatment with pegylated interferon and ribavirin. Antivir. Ther. 2011, 16, 689-694.
34. Jensen, D., Pol, S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: Ten years too late? Liver Int. 2012, 32, 74-78.
35. Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Rustgi, V., McPhee, F., Wind-Rotolo, M., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012, 366, 216-224.
36. Omata, M., Kanda, T., Yu, M.L., Yokosuka, O., Lim, S.G., Jafri, W., Tateishi, R., Hamid, S.S., Chuang, W.L., Chutaputti, A., et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 2012, 6, 409-435.
37. Miyaaki, H., Ichikawa, T., Yatsuhashi, H., Taura, N., Miura, S., Usui, T., Mori, S., Kamihira, S., Tanaka, Y., Mizokami, M., Nakao, K. Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. Hepatol. Res. 2011, 41, 1216-1222.
38. Tillmann, H.L., Patel, K., Muir, A.J., Guy, C.D., Li, J.H., Lao, X.Q., Thompson, A., Clark, P.J., Gardner, S.D., McHutchison, J.G., McCarthy, J.J. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J. Hepatol. 2011, 55, 1195-1200.
39. Toyoda, H., Kumada, H. Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: Direct or indirect? J. Hepatol. 2012, 56, 738-739.
40. Clark, P.J., Thompson, A.J., Zhu, M., Vock, D.M., Zhu, Q., Ge, D., Patel, K., Harrison, S.A., Urban, T.J., Naggie, S., et al. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. J. Viral Hepat. 2012, 19, 332-340.
41. Rembeck, K., Alsio, A., Christensen, P.B., Farkkila, M., Langeland, N., Buhl, M.R., Pedersen, C., Morch, K., Westin, J., Lindh, M., et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 2012, 7, e29370.
42. Stattermayer, A.F., Rutter, K., Beinhardt, S., Scherzer, T.M., Stadlmayr, A., Hofer, H., Wrba, F., Steindl-Munda, P., Krebs, M., Datz, C., et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J. Hepatol. 2012, in press.
43. Veldt, B.J., Duarte-Rojo, A., Thompson, A.J., Watt, K.D., Heimbach, J.K., Tillmann, H.L., Goldstein, D.D., McHutchison, J.G., Charlton, M.R. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am. J. Transplant. 2012, 12, 737-744.
44. Marabita, F., Aghemo, A., Nicola, S.D., Rumi, M.G., Cheroni, C., Scavelli, R., Crimi, M., Soffredini, R., Abrignani, S., De Francesco, R., Colombo, M. Genetic variation in the interleukin- 28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011, 54, 1127-1134.
45. Joshita, S., Umemura, T., Katsuyama, Y., Ichikawa, Y., Kimura, T., Morita, S., Kamijo, A., Komatsu, M., Ichijo, T., Matsumoto, A., et al. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum. Immunol. 2012, 73, 298-300.
46. Bochud, P.Y., Bibert, S., Kutalik, Z., Patin, E., Guergnon, J., Nalpas, B., Goossens, N., Kuske, L., Mullhaupt, B., Gerlach, T., et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012, 55, 384-394.
47. Di Marco, V., Bronte, F., Calvaruso, V., Capra, M., Borsellino, Z., Maggio, A., Renda, M.C., Pitrolo, L., Pinto, M.C.L., Rizzo, M., et al. IL28B polymorphisms influence stage of the liver fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 2012, in press.
48. Eurich, D., Boas-Knoop, S., Bahra, M., Neuhaus, R., Somasundaram, R., Neuhaus, P., Neumann, U., Seehofer, D. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012, 93, 644-649.
49. Masuzaki, R., Tateishi, R., Yoshida, H., Arano, T., Uchino, K., Enooku, K., Goto, E., Nakagawa, H., Asaoka, Y., Kondo, Y., et al. Assessment of disease progression in patients with transfusionassociated chronic hepatitis C using transient elastography. World J. Gastroenterol. 2012, 18, 1385-1390.
50. Osada, M., Kaneko, M., Sakamoto, M., Endoh, M., Takigawa, K., Suzuki-Inoue, O., Satoh, K., Enomoto, N., Yatomi, Y., Ozaki, Y. Causes of thrombocytopenia in chronic hepatitis C viral infection. Clin. Appl. Thromb. Hemost. 2012, 18, 272-280.
51. Ohira, M., Ishifuro, M., Ide, K., Irei, T., Tashiro, H., Itamoto, T., Ito, K., Chayama, K., Asahara, T., Ohdan, H. Significant correlation between spleen volume and thrombocytopenia in liver transplant patients: A concept for predicting persistent thrombocytopenia. Liver Transpl. 2009, 15, 208-215.
52. Olariu, M., Olariu, C., Olteanu, D. Thrombocytopenia in chronic hepatitis C. J. Gastrointestin. Liver Dis. 2010, 19, 381-385.